Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
Intracoronary Injection of Epo After Myocardial Infarct "Intra-CO-EpoMI"
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 54
- Registration Number
- NCT01043991
- Locations
- 🇫🇷
Montpellier University Hospital, Montpellier, France
Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.
- Conditions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2010-01-13
- Target Recruit Count
- 80
- Registration Number
- NCT01039350
- Locations
- 🇪🇸
Hospital de Cruces, Barakaldo, Bilbao, Spain
🇪🇸Hospital Virgen del Puerto, Plasencia, Caceres, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 358
- Registration Number
- NCT00925587
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 16
- Registration Number
- NCT00907608
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, China
Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease
- Conditions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 20
- Registration Number
- NCT00883415
- Locations
- 🇺🇸
Baltimore VA Medical Center, Baltimore, Maryland, United States
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2549
- Registration Number
- NCT00858364
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2825
- Registration Number
- NCT00773513
- Locations
- 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺Renal Research Dr Simon Roger, Gosford, New South Wales, Australia
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
- Conditions
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 421
- Registration Number
- NCT00717821
The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 18
- Registration Number
- NCT00647998
- Locations
- 🇺🇸
The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.
- Conditions
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT00605345
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.